Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Hecolin in Pregnant and Non-Pregnant Women
NCT05808166Phase 2Recruiting
- Sponsor
- International Vaccine Institute
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HEV 239 in hepatitis E (HEV), sponsored by International Vaccine Institute. Started May 2024; status: recruiting.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT05808166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808166.